Unlimited Email and Phone number
Everything you need to reach more inboxes and close more deals
Unlimited Contact Only at$79
Adrian Olszewski
Lecturer @Kozminski University
Signup · Get unlimited contacts
WORK HISTORY
Lecturer @Kozminski University
Project management in clinical research - Biostatistics / Zarządzanie projektami w badaniach klinicznych - Biostatystyka
EDUCATION
University of Silesia in Katowice
Bachelor of Science (BSc), Computer Science
University of Silesia in Katowice
Master of Science (MSc), Computer Science
SKILLS
ABOUT ADRIAN OLSZEWSKI
For 14 years I\'ve been developing my skills in clinical trials biostatistics (frequentist; non-Bayesian) across diverse therapeutic areas, supported by advanced statistical programming in R. I\'m experienced in integrating R into controlled, numerically validated environments. ℹ I\'m a self-taught applied biostatistician - I hold no degree in statistics or mathematics No SAS - only R. Details: Experience (years): Biostatistics: 14 Writing SAPs: 12 Programming in R: 22 TFL shells: 12 Trials RCT phase II-IV. adaptive/seamless RWE: pro-/retrospective observational Therapeutic areas in which I analysed studies: asthma · oncology · rheumatology · osteoporosis · orthopaedics (osteogenesis) · dyslipidemia · anaemia · cardiology: rhythm disorders + cardiovascular diseases · thrombophilia · periodontology · endocrinology Scope of activity:trial design: fixed & adaptive; multi-arm, cross-over/parallel + sample size & power · SAP+TFLs · randomization · analysis, programming, report · SOP Selected topics in statistics: Descriptive & inferential statistics: estimation & testing hypotheses (+ MCID: non-inferiority, equivalence, superiority). Effect size measures FWER control: CTP classic (MVT, Bonferroni, Holm, etc) and sequential (fixed/fallback/gatekeeping), graphical; FDR Modern non-parametric, robust, bootstrap & permutation methods Model-based hypothesis testing; LM, GLM (+GEE & GLMM), LQM[M], GAM Longitudinal analysis ([c]LDA, ANCOVA post/change), pre-post: conditional (mixed models) & population-average (MMRM: GLS/GEE; GEE-GLM; Firth/Exact) AME/MEM (LS/EM-means); G-calc Contingency + questionnaires (+ Likert) Type 2/3 analysis of main and interaction effects (n-way [RM]-AN[C]OVA). Simple effects / planned contrasts. · Wald, LRT, Rao PCA,(E)FA Missing data: RBMI/MICE/DR/*OCF, MNAR sensitivity Estimand framework Survival analysis:* Scope- Estimation & comparison of: survival prob./CIF, quantiles, RMST · [weighted] LogRank/Fleming-Harrington: Max-Combo/Tarone-Ware/Gehan-Breslow/Peto; Gray- Regression:(semi-)parametric · (non-)proportional hazards · time-dependent covariates · unequal effects & baseline hazards (strata) · recurrent events & competing risks (counting models, sub-distribution)+ combined (joint frailty)* Selected tools: Kaplan-Meier/Nelson-Aalen/Aalen-Johansen/Turnbull · Cox (+ext: AG/PWP/FG), AFT, Royston-Parmar, Frailty Models · landmark SMR + inference NTB via GPW; Buyse test PharmacoKinetics G-comp, IPTW, matching Guidelines: ICH, FDA, RECIST, STARD, CONSORT, STROBE
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.